journal article·2026-04Open access

Shooting two hawks with one arrow: manganese-doped mesoporous carriers coordinate STING activation and enhanced mRNA translation for in situ cytokine delivery

Yakai Yan, Liuyi Chen, Yue Wu, Xinrong Qu, Xiang Ma, Xing Sun, Guangya Xiang, Yao Lu

Abstract

Cytokine mRNAs, such as IL-12, hold significant promise for anti-tumor therapy. However, their effective localized delivery and the prevention of off-target translation remain challenging. To address these challenges, we synthesized manganese-doped organic mesoporous carriers for mRNA delivery (PMSMns). The Mn doping in PMSMns not only boosted mRNA expression but also enhanced the immune response. Mechanistically, we verified that PMSMns enhance the translation process by relieving glyceraldehyde 3-phosphate dehydrogenase-mediated translational repression and upregulating the level of phosphorylated ribosomal protein S6. Meanwhile, the immune response was enhanced by activating the stimulator of interferon genes (STING) pathway. Furthermore, effective local delivery of mRNA only in tumors without off-target expression in other organs was also achieved. The PMSMns-IL-12/15-mRNA group exhibited the highest levels of IFN-γ, the greatest infiltration of CD8+ T cells, and the most robust recruitment of NK cells, achieving a potent synergistic antitumor effect. Overall, PMSMns provide a dual benefit: boosting mRNA translation and activating the STING pathway, making them ideally suited for cytokine mRNA-based tumor therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · interferon and immune responses · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (45)

Show source-provided references
1. Designer vaccine nanodiscs for personalized cancer immunotherapy10.1038/nmat4822 ↗
2. Recent advances in engineered materials for immunotherapy-involved combination cancer therapy10.1002/adma.202007630 ↗
3. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy10.1038/s41586-019-1170-y ↗
4. Smart hypoxia-responsive transformable and charge-reversible nanoparticles for the deep penetration and tumor microenvironment modulation of pancreatic cancer10.1016/j.biomaterials.2022.121599 ↗
5. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies10.1002/adma.202007603 ↗
6. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy10.1038/s41467-022-28279-8 ↗
7. Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models10.1126/scitranslmed.abc7804 ↗
8. SON-1210-a novel bifunctional IL-12/IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy10.3389/fimmu.2023.1326927 ↗
9. Therapeutic potential of interleukin-15 in cancer10.3892/etm.2021.10107 ↗
10. The potential and promise of IL-15 in immuno-oncogenic therapies10.1016/j.imlet.2017.08.010 ↗
11. A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses10.1016/j.ymthe.2024.10.021 ↗
12. Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer10.1080/2162402X.2015.1017701 ↗
13. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity10.1038/s41565-023-01580-3 ↗
14. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity10.1038/s43018-020-0095-6 ↗
15. Targeted LNPs deliver IL-15 superagonists mRNA for precision cancer therapy10.1016/j.biomaterials.2024.123047 ↗
16. A combination of PD-L1-targeted IL-15 mRNA nanotherapy and ultrasound-targeted microbubble destruction for tumor immunotherapy10.1016/j.jconrel.2024.01.039 ↗
17. Enhanced local delivery of engineered IL-2 mRNA by porous Silica nanoparticles to promote effective antitumor immunity10.1021/acsnano.3c06733 ↗
18. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity10.1038/s41467-024-54877-9 ↗
19. Combining mRNA with PBS and calcium ions improves the efficiency of the transfection of mRNA into tumors10.1016/j.omtn.2024.102273 ↗
20. Room temperature synthesis of dendritic mesoporous silica nanoparticles with small sizes and enhanced mRNA delivery performance10.1039/C8TB00544C ↗
21. In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles10.1016/j.jconrel.2021.06.030 ↗
22. Functional nanoparticles with a reducible tetrasulfide motif to upregulate mRNA translation and enhance transfection in hard-to-transfect cells10.1002/anie.201914264 ↗
23. Confined growth of ZIF-8 in dendritic mesoporous organosilica nanoparticles as bioregulators for enhanced mRNA delivery in vivo10.1093/nsr/nwaa268 ↗
24. Engineered design of a mesoporous Silica nanoparticle-based nanocarrier for efficient mRNA delivery in vivo10.1021/acs.nanolett.2c04486 ↗
25. Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination10.1016/j.ejpb.2021.03.011 ↗
26. Development of a cancer nanovaccine to induce antigen-specific immune responses based on large-sized porous Silica nanoparticles
27. Strategies for the development of metalloimmunotherapies10.1038/s41551-024-01221-7 ↗
28. Self-Cascaded Pyroptosis-STING initiators for catalytic metalloimmunotherapy10.1021/jacs.4c12552 ↗
29. A cancer nanovaccine based on an FeAl-Layered double hydroxide framework for reactive oxygen species-augmented metalloimmunotherapy10.1021/acsnano.3c11960 ↗
30. The balance of STING signaling orchestrates immunity in cancer10.1038/s41590-024-01872-3 ↗
31. Manganese molybdate nanodots with dual amplification of STING activation for "cycle" treatment of metalloimmunotherapy
32. Manganese-coordinated nanoparticle with high drug-loading capacity and synergistic photo-/immuno-therapy for cancer treatments10.1016/j.biomaterials.2024.122745 ↗
33. Spleen-targeted mRNA vaccine doped with manganese adjuvant for robust anticancer immunity in vivo10.1021/acsnano.4c09902 ↗
34. Rational design of advanced gene delivery carriers: macrophage phenotype matters10.1002/adma.202401504 ↗
35. Biodegradable manganese-containing mesoporous silica nanoparticles for precisely controlled Quercetin delivery10.1021/acsanm.4c00168 ↗
36. Manganese-doped liquid metal nanoplatforms for cellular uptake and glutathione depletion-enhanced photothermal and chemodynamic combination tumor therapy10.1016/j.actbio.2024.11.010 ↗
37. "Manganese Extraction" strategy enables tumor-sensitive biodegradability and theranostics of nanoparticles10.1021/jacs.6b04299 ↗
38. Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles10.1016/j.jconrel.2021.05.038 ↗
39. Tailoring Iron oxide nanoparticles for efficient cellular internalization and endosomal Escape10.3390/nano10091816 ↗
40. Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma10.1016/j.apsb.2021.11.020 ↗
41. Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD+-binding region (Rossmann fold)10.1074/jbc.270.6.2755 ↗
42. Overview of perspectives on cancer, newer therapies, and future directions
43. Immunotherapy for mucosal melanoma10.1097/ot9.0000000000000019 ↗
44. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C10.1016/S1386-6346(99)00085-6 ↗
45. Evaluation of blood urea nitrogen and serum creatinine concentrations as indicators of renal dysfunction: a study of 111 cases and a review of related literature10.2460/javma.1976.168.07.593 ↗